Back to Acceleration Radar
ANIPANI Pharmaceuticals Inc
Health Care · Biotechnology: Pharmaceutical Preparations · Small
$72.61−1.55%
As of 23 Oct 2026Mkt cap $1.7B
Stage 13
AVOID
Fundamentals
52.2/75
Technical
5.0/15
Independent
57.2/90
GCAE viewstructural technical damage is a hard non-actionable condition
Price
- 1M
- −1.9%
- 3M
- −7.3%
- 6M
- −7.7%
- 1Y
- −22.6%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 15.4xHist median 37.9x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- 15.7%
- Operating margin
- 9.6%
- FCF margin
- 19.4%
- Current ratio
- 2.7x
Growth
- Revenue growth
- +43.8%Latest FY YoY
- Revenue CAGR
- +42.2%
- EPS CAGR
- +97.6%
- FCF CAGR
- +286.9%
Capital
- Share-count trend
- +8.0%3Y annualised
- Net debt
- $35M0.2x OCF
Annual trend
- CAGR 2021–2025
- +42.2%
- Latest · 2025
- $1B
- YoY
- +43.8%
GCAE Research
- Quality Research
- PRE-AI
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
structural technical damage is a hard non-actionable condition
Unresolved question
Which timing read is better supported as new price and operating evidence arrives: production v2 or research v3?
Watch next
- Next earnings · 2026-11-05
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- damaged
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- CURRENT
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded